Antibody Contract Manufacturing Market Size Worth USD 44.96 Billion by 2034 | CAGR: 9.94%

The antibody contract manufacturing market size is expected to reach USD 44.96 billion by 2034, according to a new study by Polaris Market Research. The report “Antibody Contract Manufacturing Market Share, Size, Trends, Industry Analysis Report: By Product (Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Others), By Source, By Therapeutic Area, By End User, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Antibody contract manufacturing involves the outsourced production of monoclonal antibodies, polyclonal, and bispecific antibodies, enabling biopharmaceutical companies to meet growing therapeutic and diagnostic demands. These services are executed under stringent regulatory and quality guidelines to ensure high yield, product consistency and clinical-grade safety.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/antibody-contract-manufacturing-market/request-for-sample

The market growth is fueled by the increasing global incidence of cancer and other chronic diseases, which is driving demand for targeted antibody-based therapies. Rising global R&D expenditure in oncology and immunology is further boosting the development of next-generation biologics.

Top of FormAntibody Contract Manufacturing Market Report Highlights

• Based on product, the monoclonal antibodies segment accounted for the largest market share in 2024, due to the rising number of kidney, liver, and heart transplant surgeries requiring long-term immunosuppressive therapy.
• Based on source, the mammalian segment dominated the market, driven by its high compatibility with complex protein structures and ability to produce glycosylation profiles essential for therapeutic efficacy.
• Based on therapeutic area, the infectious diseases segment is expected to witness the fastest growth, fueled by increasing demand for antibody-based therapies to combat emerging viral infections and rising prevalence of chronic infectious conditions.
• Based on end user, the biopharmaceutical companies segment held the dominant share in 2024, due to the growing trend of outsourcing antibody production to specialized CMOs for cost optimization and faster commercialization.
• North America dominated the global antibody contract manufacturing market in 2024, fueled by robust biopharmaceutical manufacturing capacity and the rapid integration of advanced biologics into production processes.
• Asia Pacific witnessed a steady growth, due to significant growth in the regional biotechnology industry, coupled with rising collaborations and outsourcing agreements with international pharmaceutical companies.
• A few global key market players include Lonza Group AG, Samsung Biologics, WuXi Biologics, Boehringer Ingelheim International GmbH, Fujifilm Diosynth Biotechnologies, Catalent, Inc., AbbVie Inc., Thermo Fisher Scientific Inc., Shilpa Medicare Ltd., Lotte Biologics, Merck Group, and Charles River Laboratories.

Polaris Market Research has segmented the market report on the basis of product, source, therapeutic area, end user, and region:

By Product Outlook (Revenue, USD Billion, 2020–2034)

• Monoclonal Antibodies
• Polyclonal Antibodies
• Bispecific Antibodies
• Others

By Source Outlook (Revenue, USD Billion, 2020–2034)

• Mammalian
• Microbial

By Therapeutic Area (Revenue, USD Billion, 2020–2034)

• Oncology
• Neurology
• Cardiology
• Infectious Diseases
• Other Therapeutic Areas

By End User (Revenue, USD Billion, 2020–2034)

• Biopharmaceutical Companies
• Research Laboratories
• Others

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America